Pathogenic mitochondrial dysfunction and metabolic abnormalities
Files
Published version
Date
2021-11
Authors
Moos, Walter H.
Faller, Douglas V.
Glavas, Ioannis P.
Harpp, David N.
Kamperi, Natalia
Kanara, Iphigenia
Kodukula, Krishna
Mavrakis, Anastasios N.
Pernokas, Julie
Pernokas, Mark
Version
OA Version
Citation
W.H. Moos, D.V. Faller, I.P. Glavas, D.N. Harpp, N. Kamperi, I. Kanara, K. Kodukula, A.N. Mavrakis, J. Pernokas, M. Pernokas, C.A. Pinkert, W.R. Powers, K. Steliou, C. Tamvakopoulos, D.G. Vavvas, R.J. Zamboni, K. Sampani. 2021. "Pathogenic mitochondrial dysfunction and metabolic abnormalities.." Biochem Pharmacol, Volume 193, pp. 114809 - ?. https://doi.org/10.1016/j.bcp.2021.114809
Abstract
Herein we trace links between biochemical pathways, pathogenesis, and metabolic diseases to set the stage for new therapeutic advances. Cellular and acellular microorganisms including bacteria and viruses are primary pathogenic drivers that cause disease. Missing from this statement are subcellular compartments, importantly mitochondria, which can be pathogenic by themselves, also serving as key metabolic disease intermediaries. The breakdown of food molecules provides chemical energy to power cellular processes, with mitochondria as powerhouses and ATP as the principal energy carrying molecule. Most animal cell ATP is produced by mitochondrial synthase; its central role in metabolism has been known for >80 years. Metabolic disorders involving many organ systems are prevalent in all age groups. Progressive pathogenic mitochondrial dysfunction is a hallmark of genetic mitochondrial diseases, the most common phenotypic expression of inherited metabolic disorders. Confluent genetic, metabolic, and mitochondrial axes surface in diabetes, heart failure, neurodegenerative disease, and even in the ongoing coronavirus pandemic.
Description
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.